Cyclin-dependent kinases as therapeutic targets in cancer: Recent advances, challenges, and opportunities - PubMed
4 days ago
- #CDK inhibitors
- #cell cycle
- #cancer therapy
- Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are attractive therapeutic targets in cancer.
- CDK inhibitors (CDKIs), especially those targeting CDK4/6, have shown clinical success in HR+/HER2- metastatic breast cancer.
- Recent structural insights into CDK2 have led to the development of selective CDK2 inhibitors with promising antitumor activity.
- Dual inhibition of CDK4/6 and CDK2 may synergistically overcome resistance to CDK4/6 inhibitors.
- CDKIs can induce cellular senescence and enhance the effectiveness of cancer immunotherapy.
- The review discusses integrating CDK-targeted therapies with immunotherapy and other treatment strategies.